Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Circ Cardiovasc Imaging. 2016 Aug;9(8):e004325. doi: 10.1161/CIRCIMAGING.115.004325

Figure 1. CMR Assessments of Myocardial T1.

Figure 1

Myocardial native T1 of control participants without cancer (965±3 ms) and cancer pre-treatment participants (1058±7 ms) compared with cancer survivors treated with anthracycline chemotherapy (1040±7 ms). Myocardial T1 is elevated in both cancer groups, reflecting potential myocardial fibrosis compared with cancer-free control participants (p<0.0001 for both).